<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476435</url>
  </required_header>
  <id_info>
    <org_study_id>D14-P009</org_study_id>
    <nct_id>NCT02476435</nct_id>
  </id_info>
  <brief_title>Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation</brief_title>
  <acronym>PERSONA</acronym>
  <official_title>Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation of Right Angular Gyrus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier St Anne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier St Anne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the therapeutic efficacy of transcranial magnetic
      stimulation in patients with depersonalization disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depersonalization disorder is characterised by a profound disruption of self-awareness.
      Depersonalization symptoms may occasionally arise (30 to 70% of the population) or may become
      chronic in depersonalization disorder. Its prevalence is around 2.4% in the general
      population. This disorder is particularly resistant to pharmacological treatments. This study
      is a randomized, double-blind, placebo-controlled study, and the investigators are testing
      the therapeutic efficacy of neuronavigated repetitive Transcranial Magnetic Stimulation (TMS)
      of right angular gyrus in patients with depersonalization disorder.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>At 3 weeks (in the end of the treatment)</time_frame>
    <description>The CDS is a comprehensive instrument containing 29 items addressing the complaints classically associated with the depersonalization syndrome. Each item is rated on two Likert scales for frequency and duration of the experience. The global score of the scale is the arithmetic sum of all items (range 0-290). High scores reflect a severe disorder.
The improvement is defined by a 50% decrease of the scores from the Cambridge depersonalization scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>At 1 month after the treatment</time_frame>
    <description>The CDS is a comprehensive instrument containing 29 items addressing the complaints classically associated with the depersonalization syndrome. Each item is rated on two Likert scales for frequency and duration of the experience. The global score of the scale is the arithmetic sum of all items (range 0-290). High scores reflect a severe disorder.
The improvement is defined by a 50% decrease of the scores from the Cambridge depersonalization scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>At 2 months after the treatment</time_frame>
    <description>The CDS is a comprehensive instrument containing 29 items addressing the complaints classically associated with the depersonalization syndrome. Each item is rated on two Likert scales for frequency and duration of the experience. The global score of the scale is the arithmetic sum of all items (range 0-290). High scores reflect a severe disorder.
The improvement is defined by a 50% decrease of the scores from the Cambridge depersonalization scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cambridge Depersonalization Scale (CDS)</measure>
    <time_frame>At 3 months after the treatment</time_frame>
    <description>The CDS is a comprehensive instrument containing 29 items addressing the complaints classically associated with the depersonalization syndrome. Each item is rated on two Likert scales for frequency and duration of the experience. The global score of the scale is the arithmetic sum of all items (range 0-290). High scores reflect a severe disorder.
The improvement is defined by a 50% decrease of the scores from the Cambridge depersonalization scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the maintenance of therapeutic efficacy at 3 months after rTMS</measure>
    <time_frame>At 3 months</time_frame>
    <description>maintenance of reduction of at least 50% of the original score to the depersonalization scale of Cambridge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of cerebral blood flow of the right angular gyrus and functional connectivity, measurement of cortical gyrification and anatomical connectivity</measure>
    <time_frame>Baseline</time_frame>
    <description>Anatomical MRI, ASL MRI, Resting State MRI, Diffusion MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of cerebral blood flow of the right angular gyrus and functional connectivity, measurement of cortical gyrification and anatomical connectivity</measure>
    <time_frame>Visit 3 : end of the TMS sessions (between 19 and 25 days after V2 - start of TMS)</time_frame>
    <description>Anatomical MRI, ASL MRI, Resting State MRI, Diffusion MRI.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Depersonalization Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental = Active rTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Comparator = Sham rTMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active rTMS</intervention_name>
    <description>Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks</description>
    <arm_group_label>Experimental = Active rTMS</arm_group_label>
    <other_name>Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo rTMS</intervention_name>
    <description>Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks</description>
    <arm_group_label>Sham Comparator = Sham rTMS</arm_group_label>
    <other_name>Magstim Super-Rapid2, Neuronavigation system Visor (ANT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  Outpatients aged over 18 years old

          -  Suffering from depersonalization disorder according to DSM IV-TR

          -  Patients currently on DPD medication must be at the same stable dose(s) at least 2
             months and must be continued at the same dose(s) through the duration of the study.

          -  Patient provided informed written consent

          -  Patient covered by a contributory social security scheme

        Controls:

          -  Aged over 18 years old

          -  Absence of a personal history of psychiatric disorders

          -  Provided informed written consent

          -  Covered by a contributory social security scheme

        Exclusion Criteria:

          -  Patients:

          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable
             cardiac disease.

          -  Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,
             or electrodes) or any other metal object within or near the head, excluding the mouth,
             that cannot be safely removed.

          -  history of neurosurgery,

          -  neurosurgical ventriculoperitoneal bypass valves

          -  personal and / or family history of seizures or epilepsy

          -  Dental device

          -  Pregnant woman

          -  Claustrophobic subjects

          -  Not cooperating or agitated patients

          -  Medications that reduce the seizure threshold, such as clozapine, bupropion, methadone
             and / or theophylline

          -  Alcohol abuse and / or toxic substances in the last 12 months

          -  Substance dependence except tobacco

        Controls:

          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable
             cardiac disease.

          -  Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants,
             or electrodes) or any other metal object within or near the head, excluding the mouth,
             that cannot be safely removed.

          -  neurosurgical ventriculoperitoneal bypass valves

          -  Claustrophobic subjects

          -  Pregnant woman

          -  Not cooperating or agitated patients

          -  Dental device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marion PLAZE, MD, PhD</last_name>
    <phone>00 33 1 45 65 76 65</phone>
    <email>m.plaze@ch-sainte-anne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie GODARD</last_name>
    <phone>00 33 1 45 65 77 28</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint-Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane MOUCHABAC, MD</last_name>
      <email>stephane.mouchabac@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion PLAZE, MD, PhD</last_name>
      <email>m.plaze@ch-sainte-anne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Blanke O, Ortigue S, Landis T, Seeck M. Stimulating illusory own-body perceptions. Nature. 2002 Sep 19;419(6904):269-70.</citation>
    <PMID>12239558</PMID>
  </reference>
  <reference>
    <citation>Blanke O. Multisensory brain mechanisms of bodily self-consciousness. Nat Rev Neurosci. 2012 Jul 18;13(8):556-71. doi: 10.1038/nrn3292. Review.</citation>
    <PMID>22805909</PMID>
  </reference>
  <reference>
    <citation>Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res. 2000 Mar 6;93(2):153-64.</citation>
    <PMID>10725532</PMID>
  </reference>
  <reference>
    <citation>Farrer C, Frey SH, Van Horn JD, Tunik E, Turk D, Inati S, Grafton ST. The angular gyrus computes action awareness representations. Cereb Cortex. 2008 Feb;18(2):254-61. Epub 2007 May 8.</citation>
    <PMID>17490989</PMID>
  </reference>
  <reference>
    <citation>Frith CD, Blakemore SJ, Wolpert DM. Abnormalities in the awareness and control of action. Philos Trans R Soc Lond B Biol Sci. 2000 Dec 29;355(1404):1771-88. Review.</citation>
    <PMID>11205340</PMID>
  </reference>
  <reference>
    <citation>Mantovani A, Simeon D, Urban N, Bulow P, Allart A, Lisanby S. Temporo-parietal junction stimulation in the treatment of depersonalization disorder. Psychiatry Res. 2011 Mar 30;186(1):138-40. doi: 10.1016/j.psychres.2010.08.022. Epub 2010 Sep 15.</citation>
    <PMID>20837362</PMID>
  </reference>
  <reference>
    <citation>Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003 Mar;17(1):103-5.</citation>
    <PMID>12680746</PMID>
  </reference>
  <reference>
    <citation>Sierra M, Baker D, Medford N, David AS. Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale. Psychol Med. 2005 Oct;35(10):1523-32.</citation>
    <PMID>16164776</PMID>
  </reference>
  <reference>
    <citation>Sierra M. Depersonalization disorder: pharmacological approaches. Expert Rev Neurother. 2008 Jan;8(1):19-26. Review.</citation>
    <PMID>18088198</PMID>
  </reference>
  <reference>
    <citation>Sierra M, David AS. Depersonalization: a selective impairment of self-awareness. Conscious Cogn. 2011 Mar;20(1):99-108. doi: 10.1016/j.concog.2010.10.018. Epub 2010 Nov 17. Review.</citation>
    <PMID>21087873</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry. 2000 Nov;157(11):1782-8.</citation>
    <PMID>11058475</PMID>
  </reference>
  <reference>
    <citation>Simeon D, Kozin DS, Segal K, Lerch B, Dujour R, Giesbrecht T. De-constructing depersonalization: further evidence for symptom clusters. Psychiatry Res. 2008 Jan 15;157(1-3):303-6. Epub 2007 Oct 23.</citation>
    <PMID>17959254</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depersonalization</keyword>
  <keyword>Derealization</keyword>
  <keyword>Embodiment</keyword>
  <keyword>Emotional numbing</keyword>
  <keyword>Transcranial magnetic stimulation</keyword>
  <keyword>Angular gyrus</keyword>
  <keyword>Temporo-parietal junction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depersonalization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

